Cagrilintide + Semaglutide / CagriSema

ID: cagrisema

Aliases: CAGRILINTIDE+SEMAGLUTIDE, CagriSema, cagrilintide semaglutide combination

Type: blend_or_combination

Route/form: subcutaneous injection in clinical-trial combination context

Status: investigational

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human

Source types: early_human, human_rct, meta_analysis

Linked sources: 7

Broad outcomes: Cardiovascular / lipids / blood pressure, Fat loss / metabolic health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• amylin receptor agonism
• GLP-1 receptor agonism
• appetite and cardiometabolic endpoints

Optimization domains

• metabolic
• obesity
• diabetes
• cardiometabolic

Research basis

• CagriSema combines cagrilintide amylin-pathway satiety biology with semaglutide GLP-1 evidence, and now has direct phase 2/3 human obesity and type 2 diabetes trial sources.
• REDEFINE and diabetes trials make it an actual combination-program entry rather than just a theoretical stack of two separate drugs.
• Blood-pressure and meta-analysis sources add cardiometabolic and safety synthesis context.

Limits, risks, and missing evidence

• CagriSema is not equivalent to approved semaglutide monotherapy or standalone cagrilintide.
• GI adverse effects, lean-mass loss, BP/heart-rate, gallbladder/pancreatitis class concerns, and discontinuation issues still need trial-context interpretation.
• Combination evidence makes attribution harder: amylin-specific, GLP-1-specific, and combined effects should be separated where possible.

Risk flags

• investigational
• metabolic endocrine
• combination tolerability
• medical supervision

Linked papers, labels, and reviews

1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with semaglutide 2.4 mg
   early_human / pubmed_cagrilintide_semaglutide_phase1b
   Randomized phase 1b coadministration study; early human bridge for cagrilintide plus semaglutide before later phase 2/3 trials.
2. Blood pressure changes with cagrilintide plus semaglutide treatment
   human_rct / pubmed_cagrisema_blood_pressure_2025
   CagriSema human cardiometabolic endpoint analysis from obesity trial data.
3. Efficacy and safety of cagrilintide plus semaglutide for overweight and obesity: systematic review and meta-analysis
   meta_analysis / pubmed_cagrisema_meta_2026
   Human evidence synthesis for CagriSema; useful for keeping combo claims separate from standalone semaglutide.
4. Co-administered once-weekly cagrilintide with semaglutide in type 2 diabetes
   human_rct / pubmed_cagrisema_t2d_phase2_2023
   Phase 2 active-controlled trial; useful bridge between early coadministration physiology and phase 3 obesity results.
5. Coadministered cagrilintide and semaglutide in adults with overweight or obesity
   human_rct / pubmed_cagrisema_redefine1_2025
   REDEFINE 1 phase 3 obesity trial for cagrilintide plus semaglutide; combo evidence should be kept separate from standalone cagrilintide claims.
6. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes
   human_rct / pubmed_cagrisema_redefine2_2025
   REDEFINE 2 phase 3 trial in obesity/overweight with type 2 diabetes.
7. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
   meta_analysis / pubmed_cagrilintide_cagrisema_meta_2024
   Meta-analysis covering cagrilintide alone and CagriSema; useful synthesis but limited by few RCTs and combination attribution issues.